Protalix BioTherapeutics reported a strong second quarter in 2026 with revenues from selling goods rising to $19.8 million, driven by sales of Elfabrio®. Total revenue for the first half of 2026 reached $53.6 million, including a $25 million milestone payment from Chiesi. The company achieved net income of $22.1 million year-to-date and reaffirmed its 2026 revenue guidance of $78-$83 million. Protalix continues to advance its PRX-115 Phase 2 clinical trial for uncontrolled gout, expecting top-line results in late 2027, and is progressing preclinical programs targeting rare renal diseases. With $40.7 million in cash and equivalents, the company is well-positioned to fund ongoing operations and clinical development.
Enovis has lowered its price target to $27 from $30 following its binding offer to acquire eCential Robotics for €155 million. This acquisition aims to strengthen Enovis's position in surgical robotics and enhance its ASTRA technology ecosystem. Desp...
Citigroup reaffirmed its Buy rating on NIO but lowered the price target from $8.20 to $7.10 due to NIO's second-quarter deliveries and revenue missing company guidance and a third-quarter outlook below Wall Street estimates. Despite a 49.4% year-over...
Yum! Brands recently sold its Pizza Hut division and CEO Christopher Lee Turner sold shares amid legal scrutiny. The company is under investigation by Pomerantz LLP for possible securities fraud following a food safety crisis linked to a cyclosporias...
Dell Technologies reported quarterly revenue of $46.97 billion and earnings per share of $7.04, both surpassing analyst expectations. The company's growth is fueled by strong demand in its AI server business, supported by a substantial $51 billion or...
Analyst BTIG upgraded Medtronic to a Buy rating and raised its price target to $100, citing strong Q1 FY2027 revenue of $9.76 billion driven by broad demand. The company is investing over $700 million in Heart Tech and Robotics, signaling a focus on ...
